Publications
5491 Results
- Journal / Conference
- European Urology Oncology Mar 23:S2588-9311(24)00054-3. doi: 10.1016/j.euo.2024.03.001. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Genitourinary
- PMID
- PMID38523017
- Study Number(s)
- S1216
Three- and seven- month prostate-specific antigen levels as prognostic markers for overall survival in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel or bicalutamide
- Journal / Conference
- Cancer Feb 22. doi: 10.1002/cncr.35264. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Palliative and End of Life Care
- PMID
- PMID38386696
- Study Number(s)
- S1820
SWOG S1820: A Pilot Randomized Trial of the Altering Intake, Managing Bowel Symptoms Intervention in Survivors of Rectal Cancer (AIMS-RC)
- Journal / Conference
- ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA), poster; J Clin Oncol 42, 2024 (suppl 3; abstr 182)
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Analysis of immune-related genes (IRGs) and their potential role in sexual dimorphism in metastatic colorectal cancer (mCRC) patients (pts)
- Journal / Conference
- ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), poster; J Clin Oncol 42, 2024 (suppl 4; abstr 509)
- Year
- 2024
- Research Committee(s)
- Prevention and Epidemiology
- Study Number(s)
- S1823
North American Patterns of Care in Clinical Stage I Testicular Cancer. Secondary Data Use Project for SWOG S1823
- Journal / Conference
- JCO Oncology Practice Apr;20(4):491-502
- Year
- 2024
- Research Committee(s)
- Cancer Care Delivery
Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL
- Journal / Conference
- J Clin Oncol 42, 2024 (suppl 3; abstr TPS430); ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA), TIP, poster
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
SWOG S2303: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS = 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
- Journal / Conference
- ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA); J Clin Oncol 42, 2024 (suppl 3; abstr 664), poster
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/A021501
Postoperative Complications Following Neoadjuvant Therapy and Surgery in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501)
- Journal / Conference
- Society of Surgical Oncology (March 20-23, 2024, Atlanta, GA) oral
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S1505
Chemotherapy Dose Density is Prognostic for Patients with Resectable Pancreas Cancer: A Secondary Analysis of SWOG S1505
- Journal / Conference
- J Natl Compr Canc Netw . 2024 Apr 29:1-6. doi: 10.6004/jnccn.2023.7099. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID38688309
- Study Number(s)
- S1505
Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505
- Journal / Conference
- J Gastrointest Surg . 2024 Mar;28(3):232-235
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- PMID
- 38445914
- Study Number(s)
- S1505